132 related articles for article (PubMed ID: 32496211)
1. Antiviral activity of PLK1-targeting siRNA delivered by lipid nanoparticles in HBV-infected hepatocytes.
Foca A; Dhillon A; Lahlali T; Lucifora J; Salvetti A; Rivoire M; Lee A; Durantel D
Antivir Ther; 2020; 25(3):151-162. PubMed ID: 32496211
[TBL] [Abstract][Full Text] [Related]
2. Polo-like-kinase 1 is a proviral host factor for hepatitis B virus replication.
Diab A; Foca A; Fusil F; Lahlali T; Jalaguier P; Amirache F; N'Guyen L; Isorce N; Cosset FL; Zoulim F; Andrisani O; Durantel D
Hepatology; 2017 Dec; 66(6):1750-1765. PubMed ID: 28445592
[TBL] [Abstract][Full Text] [Related]
3. Proteins ZNF198 and SUZ12 are down-regulated in hepatitis B virus (HBV) X protein-mediated hepatocyte transformation and in HBV replication.
Wang WH; Studach LL; Andrisani OM
Hepatology; 2011 Apr; 53(4):1137-47. PubMed ID: 21480320
[TBL] [Abstract][Full Text] [Related]
4. Preclinical Characterization of NVR 3-778, a First-in-Class Capsid Assembly Modulator against Hepatitis B Virus.
Lam AM; Espiritu C; Vogel R; Ren S; Lau V; Kelly M; Kuduk SD; Hartman GD; Flores OA; Klumpp K
Antimicrob Agents Chemother; 2019 Jan; 63(1):. PubMed ID: 30373799
[TBL] [Abstract][Full Text] [Related]
5. Activation of the Liver X Receptor Pathway Inhibits HBV Replication in Primary Human Hepatocytes.
Zeng J; Wu D; Hu H; Young JAT; Yan Z; Gao L
Hepatology; 2020 Dec; 72(6):1935-1948. PubMed ID: 32145089
[TBL] [Abstract][Full Text] [Related]
6. Targeting polo-like kinase 1 enhances radiation efficacy for head-and-neck squamous cell carcinoma.
Gerster K; Shi W; Ng B; Yue S; Ito E; Waldron J; Gilbert R; Liu FF
Int J Radiat Oncol Biol Phys; 2010 May; 77(1):253-60. PubMed ID: 20394857
[TBL] [Abstract][Full Text] [Related]
7. Interferon-inducible MX2 is a host restriction factor of hepatitis B virus replication.
Wang YX; Niklasch M; Liu T; Wang Y; Shi B; Yuan W; Baumert TF; Yuan Z; Tong S; Nassal M; Wen YM
J Hepatol; 2020 May; 72(5):865-876. PubMed ID: 31863794
[TBL] [Abstract][Full Text] [Related]
8. Novel Potent Capsid Assembly Modulators Regulate Multiple Steps of the Hepatitis B Virus Life Cycle.
Lahlali T; Berke JM; Vergauwen K; Foca A; Vandyck K; Pauwels F; Zoulim F; Durantel D
Antimicrob Agents Chemother; 2018 Oct; 62(10):. PubMed ID: 30012770
[TBL] [Abstract][Full Text] [Related]
9. Polo-like Kinase 1-targeting Chitosan Nanoparticles Suppress the Progression of Hepatocellular Carcinoma.
Wang D; Chang R; Wang G; Hu B; Qiang Y; Chen Z
Anticancer Agents Med Chem; 2017; 17(7):948-954. PubMed ID: 27671301
[TBL] [Abstract][Full Text] [Related]
10. Antiviral activity of various interferons and pro-inflammatory cytokines in non-transformed cultured hepatocytes infected with hepatitis B virus.
Isorce N; Testoni B; Locatelli M; Fresquet J; Rivoire M; Luangsay S; Zoulim F; Durantel D
Antiviral Res; 2016 Jun; 130():36-45. PubMed ID: 26971407
[TBL] [Abstract][Full Text] [Related]
11. pH-responsive hybrid nanoparticle with enhanced dissociation characteristic for siRNA delivery.
Shi M; Zhao X; Zhang J; Pan S; Yang C; Wei Y; Hu H; Qiao M; Chen D; Zhao X
Int J Nanomedicine; 2018; 13():6885-6902. PubMed ID: 30498349
[TBL] [Abstract][Full Text] [Related]
12. Efficient long-term amplification of hepatitis B virus isolates after infection of slow proliferating HepG2-NTCP cells.
König A; Yang J; Jo E; Park KHP; Kim H; Than TT; Song X; Qi X; Dai X; Park S; Shum D; Ryu WS; Kim JH; Yoon SK; Park JY; Ahn SH; Han KH; Gerlich WH; Windisch MP
J Hepatol; 2019 Aug; 71(2):289-300. PubMed ID: 31077792
[TBL] [Abstract][Full Text] [Related]
13. Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions.
Xia Y; Carpentier A; Cheng X; Block PD; Zhao Y; Zhang Z; Protzer U; Liang TJ
J Hepatol; 2017 Mar; 66(3):494-503. PubMed ID: 27746336
[TBL] [Abstract][Full Text] [Related]
14. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
[TBL] [Abstract][Full Text] [Related]
15. HBV cure: why, how, when?
Levrero M; Testoni B; Zoulim F
Curr Opin Virol; 2016 Jun; 18():135-43. PubMed ID: 27447092
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 7 agonist GS-9620 induces prolonged inhibition of HBV via a type I interferon-dependent mechanism.
Niu C; Li L; Daffis S; Lucifora J; Bonnin M; Maadadi S; Salas E; Chu R; Ramos H; Livingston CM; Beran RK; Garg AV; Balsitis S; Durantel D; Zoulim F; Delaney WE; Fletcher SP
J Hepatol; 2018 May; 68(5):922-931. PubMed ID: 29247725
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic targeting of polo-like kinase 1 using RNA-interfering nanoparticles (iNOPs) for the treatment of non-small cell lung cancer.
McCarroll JA; Dwarte T; Baigude H; Dang J; Yang L; Erlich RB; Kimpton K; Teo J; Sagnella SM; Akerfeldt MC; Liu J; Phillips PA; Rana TM; Kavallaris M
Oncotarget; 2015 May; 6(14):12020-34. PubMed ID: 25557168
[TBL] [Abstract][Full Text] [Related]
18. PLK1 and HOTAIR Accelerate Proteasomal Degradation of SUZ12 and ZNF198 during Hepatitis B Virus-Induced Liver Carcinogenesis.
Zhang H; Diab A; Fan H; Mani SK; Hullinger R; Merle P; Andrisani O
Cancer Res; 2015 Jun; 75(11):2363-74. PubMed ID: 25855382
[TBL] [Abstract][Full Text] [Related]
19. p53 is not directly relevant to the response of Polo-like kinase 1 inhibitors.
Sanhaji M; Kreis NN; Zimmer B; Berg T; Louwen F; Yuan J
Cell Cycle; 2012 Feb; 11(3):543-53. PubMed ID: 22262171
[TBL] [Abstract][Full Text] [Related]
20. Targeted Treatment of Metastatic Breast Cancer by PLK1 siRNA Delivered by an Antioxidant Nanoparticle Platform.
Morry J; Ngamcherdtrakul W; Gu S; Reda M; Castro DJ; Sangvanich T; Gray JW; Yantasee W
Mol Cancer Ther; 2017 Apr; 16(4):763-772. PubMed ID: 28138033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]